Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | completed | Phase 2 | 125 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00575146 | Ketogenic Diet for Recurrent Glioblastoma(ERGO) | completed | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00677716 | Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 41 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 24, 2014 | clinicaltrials |
| NCT00397072 | Epothilone in Recurrent Glioblastoma Patients | completed | Phase 2 | 15 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | completed | Phase 2 | 41 | Katy PetersOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00657267 | Dose-Intense Temozolomide in Recurrent Glioblastoma | completed | Phase 2 | 58 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2014 | clinicaltrials |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | completed | Phase 2 | 56 | Duke UniversityOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00337883 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00921167 | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas | completed | Phase 2 | 32 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT00610571 | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | completed | Phase 1 | 62 | Katy PetersOTHER | 1 | Oct 25, 2013 | clinicaltrials |
| NCT00385853 | PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Oct 21, 2013 | clinicaltrials |
| NCT01135875 | Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients | completed | — | 130 | University of FloridaOTHER | 1 | Oct 17, 2013 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00612430 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | completed | Phase 2 | 59 | Duke UniversityOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00762255 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00014170 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00613028 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | completed | Phase 2 | 23 | Duke UniversityOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00870181 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma(HGG-01) | completed | Phase 2 | 47 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00597493 | Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 48 | Katy PetersOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00612638 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | completed | Phase 1 | 96 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01880008 | Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma | completed | — | 5 | Washington University School of MedicineOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00004262 | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00501891 | Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00612339 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00780819 | Borderzone Sampling(BZS) | completed | N/A | 10 | Maastricht University Medical CenterOTHER | 1 | May 14, 2013 | clinicaltrials |
| NCT00671970 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | completed | Phase 2 | 57 | Duke UniversityOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00316849 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00704080 | A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00045565 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00058097 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00615927 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | completed | Phase 2 | 64 | Duke UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01100177 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | completed | Phase 2 | 12 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 11, 2013 | clinicaltrials |
| NCT00612651 | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | completed | Phase 1 | 37 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613132 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | completed | Phase 1 | 78 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | completed | Phase 1 | 49 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 30, 2014source: clinicaltrials